中华耳鼻咽喉头颈外科杂志
中華耳鼻嚥喉頭頸外科雜誌
중화이비인후두경외과잡지
CHINESE JOURNAL OF OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY
2010年
6期
465-470
,共6页
孙光明%杨旭东%许学谷%李培华%刘稳%潘利娟
孫光明%楊旭東%許學穀%李培華%劉穩%潘利娟
손광명%양욱동%허학곡%리배화%류은%반리연
组胺激动药%鼻炎%变应性%咪唑类%硫脲%P物质%受体%神经激肽1
組胺激動藥%鼻炎%變應性%咪唑類%硫脲%P物質%受體%神經激肽1
조알격동약%비염%변응성%미서류%류뇨%P물질%수체%신경격태1
Histamine agonists%Rhinitis,allergic%Imidazoles%Thiourea%Substance P%Receptors,neurokinin-1
目的 探讨组胺H3受体激动剂IMETIT对变应性鼻炎(allergic rhinitis,AR)豚鼠模型P物质(substance P,SP)及其受体(substance P receptor,SP-R)mRNA表达的影响.方法 36只清洁级豚鼠以随机数字表法分为4组,每组9只,分别为:AR模型无干预组(A组)、IMETIT干预组(B组)、组胺H1受体拮抗剂氯雷他定干预组(c组)、IMETIT联合氯雷他定干预组(D组).4组豚鼠均以卵清蛋白(ovalbumin,OVA)为致敏原,建立豚鼠AR模型,观察豚鼠30 min内喷嚏、抓鼻次数,呼吸频率及鼻黏膜病理变化.以免疫组化法检测鼻中隔黏膜中每个高倍镜视野(high power,HP)下SP阳性细胞数,以反转录-聚合酶链反应(reverse transcriptive-polymerase chain reaction,RT-PCR)测定鼻中隔黏膜中SP-R mRNA的相对表达量.采用SPSS 13.0软件对数据进行分析.结果 B组平均((x)±s,下同)喷嚏[(15.0±1.3)次]、抓鼻[(16.5±2.3)次]、呼吸频率[(76.3±4.1)次/min]较A组[分别为(23.5±2.6)次、(26.1±4.1)次和(66.5±5.8)次/min)]明显改善,差异有统计学意义(P值分别为0.000、0.000和0.001);B组SP阳性细胞数为(11.6±3.6)个/HP,SP-R mRNA的相对表达量为(0.64±0.04),较A组[分别为(27.1±9.7)个/HP、(0.83±0.03)]明显减少,差异有统计学意义(P值分别为0.000、0.000).D组喷嚏[(10.0±2.3)次]、抓鼻[(11.8±1.7)次]、呼吸频率[(90.0±5.0)次/min]与B组比较亦显著改善,差异有统计学意义(P值分别为0.000、0.002和0.000);D组SP阳性细胞数[(2.0±1.7)个/HP)]及SP-R mRNA的相对表达量(0.52±0.06)较B组亦明显减少(P值分别为0.012、0.000).B组、D组较A组豚鼠鼻黏膜病理改变减轻.析因分析显示,IMETIT联合氯雷他定对上述影响具有协同作用(F值分别为11.59、8.28、5.61、5.48、6.50,P值分别为0.002、0.008、0.025、0.027、0.017).结论 IMETIT以及IMETIT联合氯雷他定能缓解豚鼠AR的症状.IMETIT可以减少鼻黏膜中SP阳性细胞数量同时降低SP-R mRNA的表达.IMETIT和氯雷他定具有协同作用.
目的 探討組胺H3受體激動劑IMETIT對變應性鼻炎(allergic rhinitis,AR)豚鼠模型P物質(substance P,SP)及其受體(substance P receptor,SP-R)mRNA錶達的影響.方法 36隻清潔級豚鼠以隨機數字錶法分為4組,每組9隻,分彆為:AR模型無榦預組(A組)、IMETIT榦預組(B組)、組胺H1受體拮抗劑氯雷他定榦預組(c組)、IMETIT聯閤氯雷他定榦預組(D組).4組豚鼠均以卵清蛋白(ovalbumin,OVA)為緻敏原,建立豚鼠AR模型,觀察豚鼠30 min內噴嚏、抓鼻次數,呼吸頻率及鼻黏膜病理變化.以免疫組化法檢測鼻中隔黏膜中每箇高倍鏡視野(high power,HP)下SP暘性細胞數,以反轉錄-聚閤酶鏈反應(reverse transcriptive-polymerase chain reaction,RT-PCR)測定鼻中隔黏膜中SP-R mRNA的相對錶達量.採用SPSS 13.0軟件對數據進行分析.結果 B組平均((x)±s,下同)噴嚏[(15.0±1.3)次]、抓鼻[(16.5±2.3)次]、呼吸頻率[(76.3±4.1)次/min]較A組[分彆為(23.5±2.6)次、(26.1±4.1)次和(66.5±5.8)次/min)]明顯改善,差異有統計學意義(P值分彆為0.000、0.000和0.001);B組SP暘性細胞數為(11.6±3.6)箇/HP,SP-R mRNA的相對錶達量為(0.64±0.04),較A組[分彆為(27.1±9.7)箇/HP、(0.83±0.03)]明顯減少,差異有統計學意義(P值分彆為0.000、0.000).D組噴嚏[(10.0±2.3)次]、抓鼻[(11.8±1.7)次]、呼吸頻率[(90.0±5.0)次/min]與B組比較亦顯著改善,差異有統計學意義(P值分彆為0.000、0.002和0.000);D組SP暘性細胞數[(2.0±1.7)箇/HP)]及SP-R mRNA的相對錶達量(0.52±0.06)較B組亦明顯減少(P值分彆為0.012、0.000).B組、D組較A組豚鼠鼻黏膜病理改變減輕.析因分析顯示,IMETIT聯閤氯雷他定對上述影響具有協同作用(F值分彆為11.59、8.28、5.61、5.48、6.50,P值分彆為0.002、0.008、0.025、0.027、0.017).結論 IMETIT以及IMETIT聯閤氯雷他定能緩解豚鼠AR的癥狀.IMETIT可以減少鼻黏膜中SP暘性細胞數量同時降低SP-R mRNA的錶達.IMETIT和氯雷他定具有協同作用.
목적 탐토조알H3수체격동제IMETIT대변응성비염(allergic rhinitis,AR)돈서모형P물질(substance P,SP)급기수체(substance P receptor,SP-R)mRNA표체적영향.방법 36지청길급돈서이수궤수자표법분위4조,매조9지,분별위:AR모형무간예조(A조)、IMETIT간예조(B조)、조알H1수체길항제록뢰타정간예조(c조)、IMETIT연합록뢰타정간예조(D조).4조돈서균이란청단백(ovalbumin,OVA)위치민원,건립돈서AR모형,관찰돈서30 min내분체、조비차수,호흡빈솔급비점막병리변화.이면역조화법검측비중격점막중매개고배경시야(high power,HP)하SP양성세포수,이반전록-취합매련반응(reverse transcriptive-polymerase chain reaction,RT-PCR)측정비중격점막중SP-R mRNA적상대표체량.채용SPSS 13.0연건대수거진행분석.결과 B조평균((x)±s,하동)분체[(15.0±1.3)차]、조비[(16.5±2.3)차]、호흡빈솔[(76.3±4.1)차/min]교A조[분별위(23.5±2.6)차、(26.1±4.1)차화(66.5±5.8)차/min)]명현개선,차이유통계학의의(P치분별위0.000、0.000화0.001);B조SP양성세포수위(11.6±3.6)개/HP,SP-R mRNA적상대표체량위(0.64±0.04),교A조[분별위(27.1±9.7)개/HP、(0.83±0.03)]명현감소,차이유통계학의의(P치분별위0.000、0.000).D조분체[(10.0±2.3)차]、조비[(11.8±1.7)차]、호흡빈솔[(90.0±5.0)차/min]여B조비교역현저개선,차이유통계학의의(P치분별위0.000、0.002화0.000);D조SP양성세포수[(2.0±1.7)개/HP)]급SP-R mRNA적상대표체량(0.52±0.06)교B조역명현감소(P치분별위0.012、0.000).B조、D조교A조돈서비점막병리개변감경.석인분석현시,IMETIT연합록뢰타정대상술영향구유협동작용(F치분별위11.59、8.28、5.61、5.48、6.50,P치분별위0.002、0.008、0.025、0.027、0.017).결론 IMETIT이급IMETIT연합록뢰타정능완해돈서AR적증상.IMETIT가이감소비점막중SP양성세포수량동시강저SP-R mRNA적표체.IMETIT화록뢰타정구유협동작용.
Objective To explore the influence of histamine H3 receptor agonist, IMETIT and simultaneous use of IMETIT and H1-receptor antagonist, Loratadine, on the symptoms of allergic rhinitis (AR) and substance P(SP) secretion and expression of SP receptor (SP-R)mRNA in AR model in guinea pigs. Methods Guinea pigs were divided randomly into 4 groups: AR group (group A) , IMETIT group (group B), Loratadine group (group C) and IMETIT + Loratadine group (group D). The severity of AR was assessed by determining the extent of three markers of allergic symptoms (sneezing, nasal rubbing and nose blocking). The changes in the nasal mucosa were studied by pathological methods. The expression of positive cell of SP was detected by immunohistochemistry. SP-R mRNA expression in nasal mucosa was used to do reverse transcriptive-polymerase chain reaction (RT-PCR). Statistical analysis was performed using a SPSS 13. 0 software. Results In Group B, the mean (i ± s) number of sneeze [ (15. 0 ± 1. 3) times] , scratching nose [ ( 16. 5 ± 2. 3 ) times ] and respiratory frequency [ (76. 3 ± 4. 1 ) times/min ] were significantly improved than those in group A [ (23. 5 ±2. 6) times, (26. 1 ±4. 1) times and (66. 5 ±5. 8) times/min, respectively), P value were 0.000, 0.000 and 0.001, respectively]. The numbers of SP positive cells [(11. 6 ±3. 6)/HP] and SP-R mRNA expression (0.64 ±0.04 ) in group B were reduced significantly compared to group A [ (27. 1 ± 9. 7)/HP, (0. 83 ± 0. 03 ) , P value were 0. 000, 0. 000, respectively]. Sneeze [(10.0 ±2.3) times], scratching nose [(11.8 ± 1.7) times] and respiration [ (90. 0 ±5. 0) times/min] in Group D were improved significantly than those in group B (P value were 0.000, 0. 002 and 0. 000, respectively). SP-positive cells [ (2. 0 ± 1. 7)/HP] and SP-R mRNA expression (0. 52 ±0. 06) in Group D compared with group B were also significantly reduced (P value were 0. 012 and 0. 000, respectively). Pathological changes in guinea pig nasal mucosa in group B, group D were alleviated than those in group A. The combination of IMETIT and Loratadine had a synergistic effect on these effects (F value were 11. 59, 8. 28,5. 61,5.48,6. 50, respectively, P value were 0. 002, 0. 008, 0. 025, 0. 027, 0. 017). Conclusions IMETIT and the combination of IMETIT with Loratadine can effectively relieve the symptoms of AR in guinea pigs, its mechanism may be relevant to reduce SP secretion and the expression of SP-RmRNA, and the two has a synergistic effect. It may be useful as a novel therapeutic approach in nasal allergy.
